Aberrant expression of AR bearing short polyglutamine (polyQ) tracts (e.g., hAR12Q) and stabilized β-catenin has also been shown to induce the early onset of tumors and accelerate invasive prostate cancer progression relative to those carrying long polyQ tracts (e.g., hAR48Q) [193]. Here, AR is linked to prostate cancer.